Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase IV study of anti-diabetic interventions in pasireotide-treated patients with Cushing's disease or acromegaly
2012-002916-16Phase 4Completed
- Sponsor
- Novartis
- Start
- Mar 2014
- Modality
- Small Molecules, Peptides
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of pasireotide LAR in Corticotropin adenoma (ACTHoma), acromegaly and type 2 diabetes mellitus (T2DM), sponsored by Novartis. Primary endpoint: Primary endpoint: Change in HbA1c from randomization to approximately 16 weeks. Started Mar 2014; status: completed.
02
Drugs
pasireotide LAR
03
Conditions
Corticotropin adenoma (ACTHoma)acromegalytype 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on 2012-002916-16.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-002916-16.